Trending Stock News

EPS for Cambrex (CBM) Expected At $1.11; Profile of 5 Analysts Covering Progenics Pharmaceuticals, Inc. (PGNX)

Analysts expect Cambrex Corporation (NYSE:CBM) to report $1.11 EPS on February, 2.They anticipate $0.07 EPS change or 5.93% from last quarter’s $1.18 EPS. CBM’s profit would be $36.39 million giving it 12.61 P/E if the $1.11 EPS is correct. After having $0.55 EPS previously, Cambrex Corporation’s analysts see 101.82% EPS growth. The stock increased 4.28% or $2.3 during the last trading session, reaching $56. About 462,787 shares traded or 11.45% up from the average. Cambrex Corporation (NYSE:CBM) has risen 11.15% since January 19, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Brean Capital given on Thursday, August 6. The company was maintained on Wednesday, August 9 by Cantor Fitzgerald. The firm has “Buy” rating by Aegis Capital given on Thursday, October 27. Needham maintained the shares of PGNX in report on Friday, August 7 with “Buy” rating. On Monday, February 6 the stock rating was upgraded by Needham to “Strong Buy”. The stock has “Buy” rating by Needham on Tuesday, June 20. The stock has “Buy” rating by Zacks on Friday, August 7. Jefferies maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Tuesday, September 26. Jefferies has “Buy” rating and $12.0 target. The firm has “Buy” rating by Jefferies given on Thursday, June 8. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Friday, October 23 by Jefferies. See Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) latest ratings:

26/09/2017 Broker: Jefferies Rating: Buy New Target: $12.0 Maintain
09/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0000 Maintain

Investors sentiment decreased to 1.11 in Q3 2017. Its down 0.18, from 1.29 in 2017Q2. It turned negative, as 22 investors sold Progenics Pharmaceuticals, Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. Prudential Fincl has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 114,802 shares. The Switzerland-based Credit Suisse Ag has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). The Belgium-based Kbc Gp Nv has invested 0.02% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Citigroup owns 155,203 shares. Ubs Asset Management Americas has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 39,549 shares. California Employees Retirement owns 172,200 shares or 0% of their US portfolio. Susquehanna Interest Gru Llp reported 122,379 shares. Cap Fund Sa has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Thrivent Fincl For Lutherans stated it has 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Parametric Portfolio Associate Ltd Liability Com reported 119,566 shares. Fifth Third Comml Bank has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 5,000 shares. Moreover, Virginia Retirement System Et Al has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Barclays Public Limited Company reported 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Parkside Commercial Bank And Tru has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Invesco reported 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $428.65 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

The stock decreased 1.93% or $0.12 during the last trading session, reaching $6.1. About 599,942 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since January 19, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

Since August 1, 2017, it had 0 insider buys, and 3 selling transactions for $1.57 million activity. Another trade for 12,000 shares valued at $736,670 was made by KLOSK STEVEN M on Tuesday, August 1.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.84 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 18.75 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *